{"bill": {"#text": "\n\t", "form": {"current-chamber": {"#tail": "\n\t\t", "#text": "IN THE SENATE OF THE UNITED STATES"}, "#text": "\n\t\t", "congress": {"#tail": "\n    ", "#text": "113th CONGRESS"}, "#tail": "\n\t", "legis-num": {"#tail": "\n\t\t", "#text": "S. 2689"}, "official-title": {"#tail": "\n\t", "#text": "To amend title XVIII of the Social Security Act to specify coverage of continuous glucose\n\t\t\t monitoring devices, and for other purposes."}, "session": {"#tail": "\n\t\t", "#text": "2d Session"}, "distribution-code": {"#tail": "\n\t\t", "@display": "yes", "#text": "II"}, "action": {"action-date": {"#tail": "\n\t\t\t", "@date": "20140730", "#text": "July 30, 2014"}, "#tail": "\n\t\t", "action-desc": {"#tail": "\n\t\t", "#text": "\n        ", "committee-name": {"#tail": "\n      ", "@committee-id": "SSFI00", "#text": "Committee on Finance"}, "sponsor": {"#tail": " (for herself and ", "#text": "Ms. Collins", "@name-id": "S252"}, "cosponsor": {"#tail": ") introduced the following bill; which was read twice and referred to the ", "#text": "Mrs. Shaheen", "@name-id": "S324"}}, "#text": "\n\t\t\t"}, "legis-type": {"#tail": "\n\t\t", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-Senate", "@dms-id": "A1", "@public-private": "public", "legis-body": {"#tail": "\n", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n    ", "quote": {"short-title": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "act", "#text": "Medicare CGM Access Act of 2014", "@value": "Medicare CGM Access Act of 2014", "@proposed": "true"}, "#text": "\n            "}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the\n\t\t  ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n\t\t\t", "#text": "Short title"}, "#text": "\n      ", "@id": "S1"}, {"#tail": "\n  ", "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n      ", "#text": "Medicare coverage of continuous glucose monitoring devices"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n        ", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 1861 of the Social Security Act", "@value": "Social Security Act/s:1861"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "42 U.S.C. 1395x", "@value": "usc/42/1395x"}, "@parsable-cite": "usc/42/1395x", "#text": "\n            ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In general"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n          ", "#text": "in subsection (s)(2)\u2014"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "#text": "\n          ", "@id": "ide851762c52824a6e8e3ab8c6cb63e79c", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n          ", "quote": {"#tail": " at the end;", "#text": "and"}, "#text": "in subparagraph (EE), by striking "}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "id38daa3dff42c4594aed44106ed86e089", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n          ", "quote": {"#tail": "; and", "#text": "and"}, "#text": "in subparagraph (FF), by adding "}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "@id": "idc3860b50fcad485fb7d426e1925383c4", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n            ", "#text": "by adding at the end the following new subparagraph:"}, "enum": {"#tail": "\n            ", "#text": "(C)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n            ", "#text": "; and"}, "#tail": "\n          ", "@id": "ide618f1f538a9442693b4e73369a669e7", "@display-inline": "no-display-inline", "#text": "\n              ", "subparagraph": {"@indent": "up1", "#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "continuous glucose monitoring devices (as defined in subsection (iii)(1)) furnished to a CGM\n\t\t\t qualified individual (as defined in subsection (iii)(2));"}, "enum": {"#tail": "\n                ", "#text": "(GG)"}, "#text": "\n                ", "@id": "idc47505fe5f85431495251ccd8772afef"}}, "#text": "\n            ", "@id": "idaff3d1c091e745afbe31302db2c9178b"}]}, {"#tail": "\n      ", "text": {"#tail": "\n          ", "#text": "by adding at the end the following new subsection:"}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "quoted-block": {"@style": "other", "after-quoted-block": {"#tail": "\n          ", "#text": "."}, "#tail": "\n        ", "subsection": {"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "(iii)"}, "header": {"#tail": "\n              ", "#text": "Continuous Glucose Monitoring Device; CGM qualified individual"}, "paragraph": [{"#tail": "\n              ", "@id": "id298D455B8A4C4D5299A01599005F72B8", "enum": {"#tail": "\n                ", "#text": "(1)"}, "@display-inline": "yes-display-inline", "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " that continuously\n\t\t\t monitors and trends glucose levels in body fluid.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, "term": {"#tail": "  means a class III medical device approved by the ", "#text": "continuous glucose monitoring device"}, "#text": "The term "}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@display-inline": "yes-display-inline", "#text": "\n                  ", "@id": "idB363423143FD4DA2ABB98646FD43878E", "@commented": "no"}, {"@indent": "up2", "#tail": "\n                ", "text": {"#tail": "\n                  ", "#text": "Such term applies to such medical device\u2014"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n                  ", "#text": "as a stand-alone product;"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@id": "id21C202593DE94E1483C32A74D919F422", "#text": "\n                    "}, {"#tail": "\n                  ", "text": {"#tail": "\n                  ", "#text": "when integrated with an insulin pump; or"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@id": "id8BD1ED5510434BCB8913BFC9EB9C7BFD", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n                  ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", such as artificial pancreas device systems.", "@entity-type": "federal-body", "#text": "Food and Drug\n\t\t\t Administration", "@entity-id": "7524"}, "#text": "as an integral component of any other medical device cleared or approved by the "}, "enum": {"#tail": "\n                    ", "#text": "(iii)"}, "@id": "id2B001F3DB4724F1786E62F1479652669", "#text": "\n                    "}], "#text": "\n                  ", "@id": "id9A7B6ED31D5640E8B395C34AFAF38512"}, {"@indent": "up2", "#tail": "\n                ", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall treat an insulin pump or other\n\t\t\t medical device that has a continuous glucose monitoring device as an\n\t\t\t integrated or integral component as a single medical device.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "With respect to a continuous glucose monitoring device that is described in clause (ii) or (iii) of\n\t\t\t subparagraph (B), the "}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "#text": "\n                  ", "@id": "idCD61D8F5878A4AB39E4918A0E4EFC809"}, {"@indent": "up2", "#tail": "\n              ", "text": {"#tail": "\n                ", "#text": "Such term includes components, accessories, and supplies that are necessary and related to the\n\t\t\t operation of the class III medical device, such as sensors, transmitters,\n\t\t\t receivers, and requisite software."}, "enum": {"#tail": "\n                  ", "#text": "(D)"}, "#text": "\n                  ", "@id": "id20BD7A99306640BC9713B5E9ABD0E057"}], "@commented": "no"}, {"@indent": "up1", "#tail": "\n              ", "text": {"#tail": "\n                ", "term": {"#tail": " means any of the following:", "#text": "CGM qualified individual"}, "#text": "The term "}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "#text": "\n                ", "@id": "id711f201e5a5f4d85a83ee3936b43f9ec", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n                  ", "#text": "An individual with Type I diabetes\u2014"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n                  ", "#text": "who is following an intensive insulin treatment regimen that consists of 3 or more insulin\n\t\t\t injections per day or the use of a subcutaneous insulin infusion pump;"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@id": "id493c9b8c93004291a7922234f15b82b7", "#text": "\n                    "}, {"#tail": "\n                  ", "text": {"#tail": "\n                  ", "#text": "subject to paragraph (3), whose attending physician certifies that the individual\u2019s condition\n\t\t\t cannot be safely and effectively managed with self-monitoring of blood\n\t\t\t glucose; and"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@id": "id3aea087ccb4f49c18e3536270e6d3811", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n                    ", "#text": "who\u2014"}, "enum": {"#tail": "\n                    ", "#text": "(iii)"}, "subclause": [{"#tail": "\n                    ", "text": {"#tail": "\n                    ", "#text": "has been unable to achieve optimum glycemic control in accordance with evidence-based guidelines;\n\t\t\t or"}, "enum": {"#tail": "\n                      ", "#text": "(I)"}, "@id": "idfba50e81806e4406819869221d890d92", "#text": "\n                      "}, {"#tail": "\n                  ", "text": {"#tail": "\n                    ", "#text": "has experienced hypoglycemia unawareness or frequent hypoglycemic episodes."}, "enum": {"#tail": "\n                      ", "#text": "(II)"}, "@id": "idf3d39fdf4b544980ad49356fbd0f536f", "#text": "\n                      "}], "#text": "\n                    ", "@id": "ide4ec2cfb2f904cdf9a7516d2ea4a941b"}], "#text": "\n                  ", "@id": "id640c599d3b564cf599da776833212d2d"}, {"#tail": "\n                ", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " may specify for the furnishing of a continuous glucose\n\t\t\t monitoring device based on available medical evidence and taking into\n\t\t\t account any anticipated pathway to the development of artificial pancreas\n\t\t\t device systems.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "An individual not described in subparagraph (A) who meets such other medical criteria as the\n\t\t\t "}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@id": "id9a098d080dfd40c7ad6c55ba93c4dac2", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", or enrolling in ", "@entity-type": "act", "#text": "part A", "@value": "Social Security Act/pt:A"}, {"#tail": ", or both.", "@entity-type": "act", "#text": "part\n\t\t\t B", "@value": "Social Security Act/pt:B"}], "#text": "An individual with diabetes who has been regularly using a continuous glucose monitoring device\n\t\t\t before becoming entitled to, or enrolling in, "}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@id": "idce9b3e03108f40cd9905c1ce45080dc4", "#text": "\n                  "}]}, {"@indent": "up1", "#tail": "\n            ", "text": {"#tail": "\n              ", "#text": "For purposes of a certification by an attending physician described in paragraph (2)(A)(ii), such\n\t\t\t certification shall not be required more frequently than once every 3\n\t\t\t years."}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "#text": "\n                ", "@id": "id1f053bad57fa473db9cfbdb302702772"}], "#text": "\n              ", "@id": "idc02fd9f1f0c3451e8dfdf4438ee6260d"}, "@other-style": "archaic", "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "idd0ff7b12a5644b979921b5d330bead82"}, "#text": "\n          ", "@id": "idca750b6f43aa4278a895a3d14f018eec"}], "#text": "\n        ", "@id": "idc71eb9edc323493f9a665395958ed4b4"}, {"#tail": "\n      ", "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Payment"}, "paragraph": [{"#tail": "\n        ", "@id": "id0335961b3778404d96fb660bff765900", "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "In general"}, "text": {"#tail": "\n          ", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 1833(a)(1) of the Social Security Act", "@value": "Social Security Act/s:1833/ss:a/p:1"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "42 U.S.C. 1395l(a)(1)", "@value": "usc/42/1395l/a/1"}, "@parsable-cite": "usc/42/1395l", "#text": "\n              ", "@legal-doc": "usc"}}}, "#text": "\n          ", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n          ", "quote": [{"#tail": " before ", "#text": "and"}, {"#tail": "; and", "#text": "(Z)"}], "#text": "by striking "}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "id03791EA950104805BD7A820DCD0E3AE4", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "quote": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": "), the amount paid shall be an amount equal to 80 percent of\n\t\t\t the amount determined under the fee schedule established under ", "@entity-type": "act", "#text": "section\n\t\t\t 1861(s)(2)(GG)", "@value": "Social Security Act/s:1861/ss:s/p:2/sp:GG", "@proposed": "true"}, {"#tail": "\n              ", "@entity-type": "act", "#text": "section\n\t\t\t 1834(p)", "@value": "Social Security Act/s:1834/ss:p", "@proposed": "true"}], "#text": ", and (AA) with respect to\n\t\t\t continuous glucose monitoring devices under "}, "#text": "by inserting before the semicolon at the end the following: "}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "@id": "idB0E8C7BD2C404A50B1C1A5A6A392F45A", "#text": "\n            "}]}, {"#tail": "\n      ", "text": {"#tail": "\n          ", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the end the\n\t\t\t following new subsection:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 1834 of the Social Security Act", "@value": "Social Security Act/s:1834"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "42 U.S.C. 1395m", "@value": "usc/42/1395m"}, "@parsable-cite": "usc/42/1395m", "#text": "\n              ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Conforming amendment"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n          ", "#text": "."}, "#tail": "\n        ", "subsection": {"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "(p)"}, "header": {"#tail": "\n              ", "#text": "Fee schedule for continuous glucose monitoring devices"}, "paragraph": [{"#tail": "\n              ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ")\n\t\t\t furnished during a year, the amount of payment under this part for such\n\t\t\t devices shall be determined under a fee schedule established by the\n\t\t\t ", "@entity-type": "act", "#text": "section 1861(iii)(1)", "@value": "Social Security Act/s:1861/ss:iii/p:1", "@proposed": "true"}, {"#tail": " in accordance with this subsection.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "With respect to continuous glucose monitoring devices (as defined in "}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "header": {"#tail": "\n                  ", "#text": "In general"}, "#text": "\n                  ", "@id": "idf1f40b97405f47baa16fa28eda925500"}, {"#tail": "\n              ", "text": {"#tail": "\n                ", "#text": "Payment shall be calculated and made under the fee schedule established under this subsection for\n\t\t\t any insulin pump or other medical device that has a continuous glucose\n\t\t\t monitoring device as an integrated or integral component."}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "header": {"#tail": "\n                  ", "#text": "Clarification of application of fee schedule to devices having CGM as an integral component"}, "#text": "\n                  ", "@id": "idef502c1ecc73449c9a2ff2768c452403"}], "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "Establishment"}, "#text": "\n                ", "@id": "idaf7b46bf13ce41f6a66038a9923bcf08"}, {"#tail": "\n              ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall\n\t\t\t establish an initial payment rate under the fee schedule established under\n\t\t\t this subsection for the first year, which may be a partial year, during\n\t\t\t which payment may be made for such continuous glucose monitoring device\n\t\t\t under this part.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "With respect to each distinct type of continuous glucose monitoring device, the "}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "header": {"#tail": "\n                  ", "#text": "In general"}, "#text": "\n                  ", "@id": "id53134c9a5fb74ba89111b2186b027389"}, {"#tail": "\n                ", "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n                  ", "#text": "reflect market rates for such device; and"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@id": "id4AE03035F2774108A6BD8D805A4057BB", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n                  ", "#text": "take into\n\t\t\t account the most recent available data on prices for such device."}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@id": "idDC76C9F001814BE4B2BB26E53D84643B", "#text": "\n                    "}], "enum": {"#tail": "\n                  ", "#text": "(B)"}, "header": {"#tail": "\n                  ", "#text": "Data"}, "text": {"#tail": "\n                  ", "#text": "With respect to a continuous glucose monitoring device, the initial payment rate under subparagraph\n\t\t\t (A) shall\u2014"}, "#text": "\n                  ", "@id": "id8115c31c60b94d778afa00149b6d4c16"}, {"#tail": "\n              ", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall\n\t\t\t establish a new HCPCS code for each distinct type of class III medical\n\t\t\t device cleared or approved by the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " that\n\t\t\t includes a continuous glucose monitoring device, such as a medical device\n\t\t\t described in ", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, {"#tail": " or ", "@entity-type": "act", "#text": "clause (ii)", "@value": "Social Security Act/s:1861/ss:iii/p:1/sp:B/cl:ii", "@proposed": "true"}, {"#tail": ".\tSuch HCPCS\n\t\t\t codes shall distinguish among the different functionalities of such\n\t\t\t devices in a manner that reflects the classifications of the ", "@entity-type": "act", "#text": "(iii) of section 1861(iii)(1)(B)", "@value": "Social Security Act/s:1861/ss:iii/p:1/sp:B/cl:iii", "@proposed": "true"}, {"#tail": " in clearing or approving such devices.", "@entity-type": "federal-body", "#text": "Food and Drug\n\t\t\t Administration", "@entity-id": "7524"}], "#text": "For purposes of the initial payment rates established under subparagraph (A), the "}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "header": {"#tail": "\n                  ", "#text": "Accounting for differences in functionalities among various CGM devices"}, "#text": "\n                  ", "@id": "idaef28fd2b940469898d55fc958b77f2a"}], "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Initial payment rate"}, "#text": "\n                ", "@id": "idebdd563e68e14fdb929327e1d876f9cd"}, {"#tail": "\n              ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall provide for\n\t\t\t annual updates to the payment rate under the fee schedule established\n\t\t\t under this subsection for each such device for the preceding year by the\n\t\t\t percentage increase in the consumer price index for all urban consumers\n\t\t\t (United States city average) for the 12-month period ending with June of\n\t\t\t the preceding year.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "With respect to each year beginning after the year, or partial year, referred to in paragraph\n\t\t\t (2)(A)\n\t\t\t during which an initial payment rate is established for a distinct\n\t\t\t continuous glucose monitoring device, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n                ", "#text": "Updates to payment rates", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "idfcca5ca2a22f4ef2a03ca8aa88880969", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall provide for adjustments to the payment rates under the fee schedule established\n\t\t\t under this subsection to take into account geographic variations in the\n\t\t\t prices of continuous glucose monitoring devices.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The "}, "enum": {"#tail": "\n                ", "#text": "(4)"}, "header": {"#tail": "\n                ", "#text": "Adjustment for geographic variations"}, "#text": "\n                ", "@id": "id8ac7db4597c3487a9c40a98b68c9157c"}], "#text": "\n              ", "@id": "id09154604fe624f029f577f75e62c7d76"}, "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "id64a89a40c61441a19bd452d4e0c4ef46"}, "#text": "\n          ", "@id": "idd5f6c6b165614afbbf591dfdc03d9ea9"}], "#text": "\n        ", "@id": "id5c1b376d81a2447f9f8ddd2a89e0cb36"}, {"#tail": "\n      ", "text": {"#tail": "\n        ", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the end\n\t\t\t the following new paragraph:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 1847(a) of the Social Security Act", "@value": "Social Security Act/s:1847/ss:a"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "\n            42 U.S.C. 1395w\u20133(a)", "@value": "usc/42/1395w\u20133/a"}, "@parsable-cite": "usc/42/1395w-3", "#text": "\n              ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Ensuring beneficiary access to appropriate components"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n      ", "paragraph": {"#tail": "\n          ", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ")\n\t\t\t that are furnished to CGM qualified individuals (as defined in ", "@entity-type": "act", "#text": "section 1861(iii)(1)", "@value": "Social Security Act/s:1861/ss:iii/p:1", "@proposed": "true"}, {"#tail": "), the ", "@entity-type": "act", "#text": "section\n\t\t\t 1861(iii)(2)", "@value": "Social Security Act/s:1861/ss:iii/p:2", "@proposed": "true"}, {"#tail": " shall ensure that such CGM qualified\n\t\t\t individuals are furnished the brand of diabetic testing supplies (as\n\t\t\t defined in subparagraph (B)) that function with such continuous glucose\n\t\t\t monitoring devices, such as in the case where there is only one brand of\n\t\t\t glucose meter that is compatible with a particular continuous glucose\n\t\t\t monitoring device.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "In carrying out the programs under this section with respect to glucose meters required for\n\t\t\t continuous glucose monitoring devices (as defined in "}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "header": {"#tail": "\n              ", "#text": "In general"}, "#text": "\n              ", "@id": "id93440d0ebcef41ac9ea7cf46ac8ccd0a"}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "term": {"#tail": " means glucose meters and diabetic testing strips.", "#text": "diabetic testing supplies"}, "#text": "In this paragraph, the term "}, "enum": {"#tail": "\n              ", "#text": "(B)"}, "header": {"#tail": "\n              ", "#text": "Definition"}, "#text": "\n              ", "@id": "idf901fc5ca9c54aafabac237f42d25c07"}], "enum": {"#tail": "\n            ", "#text": "(8)"}, "header": {"#tail": "\n            ", "#text": "Ensuring beneficiary access to appropriate components"}, "#text": "\n            ", "@id": "id8d1f45337aad4cfea28a6eafb0749894"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "id262ef288bf3349baa85b1bf7ddd27b07"}, "#text": "\n        ", "@id": "id654c5699fcbd42e99fb8acdd620ff122"}, {"#tail": "\n    ", "enum": {"#tail": "\n        ", "#text": "(d)"}, "header": {"#tail": "\n        ", "#text": "Effective date; Rulemaking"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n        ", "#text": "The amendments made by this section shall apply to items and services furnished\n\t\t\t on or after January 1, 2015."}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "Effective date"}, "#text": "\n          ", "@id": "idE4126FFD1BD9411192192772AA3FB0AD"}, {"#tail": "\n      ", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (in this paragraph referred to as the ", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, "#text": "The ", "quote": {"#tail": ") shall implement the amendments made by this section through notice and comment rulemaking.", "#text": "Secretary"}}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "header": {"#tail": "\n            ", "#text": "In general"}, "#text": "\n            ", "@id": "idE61C442A4FEC4BFF8316CB2A02990965"}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall consult with national\n\t\t\t organizations representing individuals with diabetes, physicians with\n\t\t\t relevant clinical expertise in endocrinology, and other relevant\n\t\t\t stakeholders to develop clinical criteria for the determination of whether\n\t\t\t an individual qualifies as having Type I diabetes under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", as added by subsection (a)(2).\n\t\t\t  Not later than 60 days after the date of enactment of this Act, the\n\t\t\t ", "@entity-type": "act", "#text": "section\n\t\t\t 1861(iii)(2)(A) of the Social Security Act", "@value": "Social Security Act/s:1861/ss:iii/p:2/sp:A", "@proposed": "true"}, {"#tail": " shall convene a meeting of those stakeholders to develop\n\t\t\t consensus recommendations for such clinical criteria. The ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " shall\n\t\t\t take such recommendations into account in implementing the amendments made\n\t\t\t by this section.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "As part of the rulemaking process under subparagraph (A), the "}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "header": {"#tail": "\n            ", "#text": "Consultation"}, "#text": "\n            ", "@id": "id83361649e5d04cb8af7424371d4b2d8e"}], "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Rulemaking"}, "#text": "\n          ", "@id": "idDE0B6F20551E4C0C9A54D0339A45B64C"}], "#text": "\n        ", "@id": "id8e5824aa05c64f5db8636e03315683bd"}], "#text": "\n      ", "@id": "ida19d8d31d2c5465f9468cc5cb591424e"}], "#text": "\n\t\t"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2014-07-30"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 S2689 IS: Medicare CGM Access Act of 2014"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. Senate"}, "#text": "\n"}, "#text": "\n"}}}